Related Experiment Videos
Design and tumor targeting of anthracyclines able to overcome multidrug resistance: a double-advantage approach
1Department of Clinical Investigation, University of Texas, M.D. Anderson Cancer Center, Houston 77030.
Abstract:
A novel, 'double-advantage approach' to developing more effective chemotherapies will be reviewed. This approach is based on a presumption that analogs designed on a sound hypothesis, and combined with a rationally selected drug delivery system, will optimize antitumor activity by creating drugs that are more active and that can be more specifically targeted to tumors. In the design of drugs superior to doxorubicin, we have focused on typical multidrug resistance and new anthracycline analogs, whose uptake is not affected by P-glycoprotein. Analysis of structural elements of anthracyclines affecting activity against multidrug resistant tumors and affinity for liposomes will be discussed. Annamycin, a lipophilic anthracycline analog, was selected for further preclinical development as a liposomal formulation and demonstrated, in the initial biological evaluation, high activity against tumors resistant to doxorubicin.
Insights
A new
Area of Science:
- Oncology
- Pharmacology
- Drug Development
Background:
- Multidrug resistance (MDR) is a major challenge in cancer chemotherapy.
- P-glycoprotein (P-gp) is a key efflux pump contributing to MDR.
- Doxorubicin resistance necessitates the development of novel therapeutic agents.
Purpose of the Study:
- To review a 'double-advantage approach' for developing enhanced chemotherapy drugs.
- To design novel anthracycline analogs overcoming typical multidrug resistance.
- To optimize antitumor activity through targeted drug delivery systems.
Main Methods:
- Focus on developing anthracycline analogs with uptake independent of P-glycoprotein.
- Analysis of structural features influencing activity against MDR tumors.
- Evaluation of anthracycline affinity for liposomal drug delivery.
Main Results:
- Annamycin, a lipophilic anthracycline analog, was identified.
- Liposomal formulation of Annamycin was developed.
- Initial preclinical evaluation showed high activity against doxorubicin-resistant tumors.
Conclusions:
- The 'double-advantage approach' shows promise for overcoming drug resistance.
- Annamycin represents a potential new chemotherapeutic agent for resistant cancers.
- Liposomal delivery enhances the efficacy of novel anthracycline analogs.